TIGIT
Novartis Licenses BeiGene’s Antibody for a Potential $2.8 Billion After Its Own Drug Disappoints
2021-12-21
With their Respective Immunotherapy Drugs, Arcus, AstraZeneca Combine to Combat Lung Cancer
2020-11-01